Relying solely on BMI to diagnose obesity may be outdated, say global experts. A new report calls for a more comprehensive ...

Eighty percent of doctors in a Medscape survey answered no when asked, “Is enough known about obesity meds’ risk to ...

Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.

A comprehensive review found that being out of shape greatly increased the risk of dying prematurely — regardless of age or ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

The average American woman weighs about 170 pounds and stands about 5 feet, 4 inches tall. But it’s important to remember ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Healthcare stocks, especially biopharmaceuticals, are forecasted to outperform the market due to four key investment themes.

America is suddenly getting healthier. No one knows why.